ANEMIA IN PATIENTS ON COMBINED ANDROGEN BLOCK THERAPY FOR PROSTATE CANCER

• 来源期刊: 亚洲男性学杂志(英文版)
• 学科: 医学
• 年，卷（期）: 2004,（4）
• 页码范围: 383-384
• 页数: 2页
• 分类号: R737.25
• 语种: 中文

摘要

Aim: To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer. Methods: One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy. Results: The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05). Conclusion: Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.